Certolizumab pegol

Certolizumab pegol ?
Monoclonal antibody
Type Fab' fragment
Source Humanized (from mouse)
Target TNF alpha
Clinical data
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a608041
Pregnancy cat. B(US)
Legal status -only (US)
Routes Subcutaneous
CAS number 428863-50-7 N
ATC code L04AB05
KEGG D03441 YesY
Chemical data
Formula C2115H3252N556O673S16 
Mol. mass 47.75 kDa
 N(what is this?)  pegol (verify)

Certolizumab pegol [1] (CDP870, tradename Cimzia) is a therapeutic monoclonal antibody produced by UCB for the treatment of Crohn's disease[2] and rheumatoid arthritis.[3][4][5]


Method of action

Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.[6]

Clinical trials

Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus placebo in moderate to severe active Crohn's disease.[2][6][7][8] In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-α agents.[citation needed]

Preliminary results of the RAPID 1 and 2 phase III studies were also reportedly positive.[9][10]

Legal status

On April 22, 2008, the U.S. Food and Drug Administration (FDA) approved Cimzia for use in the United States for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy.[4][11][12]

On June 26, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA on October 1, 2009.[13]


  1. ^ Goel, Niti; Sue Stephens (2010). "Certolizumab pegol". MAbs 2 (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232. PMID 20190560. http://www.landesbioscience.com/journals/17/article/11271/. 
  2. ^ a b Sandborn WJ, Feagan BG, Stoinov S, et al. (July 2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228–38. doi:10.1056/NEJMoa067594. PMID 17634458. 
  3. ^ Kaushik VV, Moots RJ (April 2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert opinion on biological therapy 5 (4): 601–6. doi:10.1517/14712598.5.4.601. PMID 15934837. 
  4. ^ a b "Cimzia Label and Approval History". Drugs@FDA. U.S. Food and Drug Administration (FDA). http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Label_ApprovalHistory. Retrieved 2009-11-15. 
  5. ^ "Cimzia Medication Guide" (PDF). U.S. Food and Drug Administration (FDA). May 2009. http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088571.pdf. Retrieved 2009-11-15. 
  6. ^ a b Schreiber S. et al.,Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase 3 study (precise),Gut,2005,54,suppl7,A82
  7. ^ Sandborn et al., Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase 3 study (PRECiSE 1),Gastroenterology, 2006,130,A107
  8. ^ "New Analysis Shows Cimzia (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn’s Disease" (Press release). UCB. October 23, 2006. http://ir.ucb-group.com/phoenix.zhtml?c=137495&p=irol-newsArticle&ID=919693. Retrieved 2009-11-15. 
  9. ^ Keystone E, Mason D, Combe B (June 14 , 2007). "The anti-TNF certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in the treatment of patients with active rheumatoid arthritis: preliminary results from the RAPID 1 study". Ann Rheum Dis 6 (Suppl 2): 55–b. doi:10.1136/ard.6.1.55. http://eular.bmj.com/cgi/content/abstract/66/Suppl_2/55-b. Retrieved 2009-11-15. 
  10. ^ Kleinman, DM (June 16, 2007). "Certolizumab, First PEGylated TNF-Blocker, May Surpass Older Drugs in Efficacy, Safety". Muskuloskeletal Report. http://www.mskreport.com/articles.cfm?articleID=1371. Retrieved 2009-11-15. 
  11. ^ UCB press release - Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease. Retrieved April 22, 2008.
  12. ^ Waknine, Yael (May 1, 2008). "FDA Approvals: Patanase, Actonel, Cimzia". Medscape. http://www.medscape.com/viewarticle/573833. Retrieved 2008-05-01. 
  13. ^ "Cimzia European Public Assessment Report". European Medicines Agency. http://www.emea.europa.eu/humandocs/Humans/EPAR/cimzia/cimzia.htm. Retrieved November 15, 2009. 

External links